After the bell, the maker of genetic analysis technologies had added 9.1% to $161.48.
Over the three months to March, the company reported net income of 53 cents a share and revenue of $420.78 million. Analysts polled by Thomson Reuters had forecast net income of 44 cents a share and $391.76 million in revenue.
Management said it has increased full-year guidance to 21% to 23% revenue growth and earnings between $2.10 and $2.15 a share. Analysts had forecast 18.2% revenue growth and earnings of $2.05 a share.
Must Read: Warren Buffett's 10 Favorite Growth Stocks